Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
sábado, octubre 24
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Tonix Pharmaceuticals Holding Corp
TNXP
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$5.17
0.04
0.78%
Últ. Act.: Oct 23, 7:43 PM
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Opciones
Informe de acciones
Tonix Pharmaceuticals Financials
Tonix Pharmaceuticals (TNXP) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Tonix Pharmaceuticals Q2 EPS $(2.44) Beats $(2.64) Estimate, Sales $13.544M Beat $7.723M Estimate
Tonix Pharmaceuticals (NASDAQ:TNXP) reported quarterly losses of $(2.44) per share which beat the analyst consensus estimate of $(2.64) by 7.58 percent. This is a 36.79 percent increase over losses of $(3.86) per share
Benzinga Newsdesk
PRO
Tonix Pharmaceuticals Q1 EPS $(2.93) Misses $(2.43) Estimate, Sales $6.878M Beat $6.100M Estimate
Tonix Pharmaceuticals (NASDAQ:TNXP) reported quarterly losses of $(2.93) per share which missed the analyst consensus estimate of $(2.43) by 20.58 percent. This is a 3.17 percent decrease over losses of $(2.84) per share
Benzinga Newsdesk
Tonix Pharmaceuticals Says Prescriptions For Chronic Pain Drug Top 4,200 Since Launch
Tonix Pharmaceuticals beats expectations, and Tonmya prescriptions grow, with over 4,200 prescriptions since launch.
Vandana Singh
PRO
Tonix Pharmaceuticals Q4 EPS $(3.98) Misses $(3.16) Estimate, Sales $5.390M Beat $2.883M Estimate
Benzinga Newsdesk
PRO
Tonix Pharmaceuticals Q3 EPS $(3.59) Misses $(3.58) Estimate, Sales $3.290M Beat $3.100M Estimate
Tonix Pharmaceuticals (NASDAQ:TNXP) reported quarterly losses of $(3.59) per share which missed the analyst consensus estimate of $(3.58) by 0.14 percent. This is a 84.17 percent increase over losses of $(22.68) per
Benzinga Newsdesk
Crude Oil Moves Higher; US Homebuilder Sentiment Declines In August
Avi Kapoor
